Expected to observed ratio of the prediction models in EPIC-NL, EPIC-Potsdam and SMART
| Risk score | Expected to observed ratio (95% CI) | ||
|---|---|---|---|
| EPIC-NL | EPIC-Potsdam | SMART | |
| CVD prediction models | 11.5% | 3.7% | 5.7% |
| Mukamal et al (CHS)19 | 1.06 (0.81 to 1.40) | 1.12 (0.83 to 1.50) | 1.23 (0.87 to 1.73) |
| Kengne et al (ADVANCE)21 | 1.17 (0.90 to 1.54) | 1.22 (0.91 to 1.65) | 1.44 (1.02 to 2.02) |
| Davis et al (Fremantle)22 | 1.18 (0.90 to 1.55) | 1.20 (0.89 to 1.62) | 1.46 (1.04 to 2.05) |
| Elley et al (DCS)20 | 1.07 (0.82 to 1.41) | 1.08 (0.80 to 1.45) | 1.15 (0.82 to 1.62) |
| Cederholm et al (NDR)23 | 1.14 (0.87 to 1.49) | 1.24 (0.92 to 1.66) | 1.34 (0.96 to 1.89) |
| CHD prediction models | 7.1% | 2.1% | 2.7% |
| Elley et al (DCS)20 | 1.10 (0.78 to 1.56) | 1.11 (0.75 to 1.66) | 1.24 (0.76 to 2.02) |
| Yang et al (HKDR)25 | 1.10 (0.78 to 1.56) | 1.12 (0.75 to 1.67) | 1.22 (0.75 to 1.99) |
| Donnan et al (DARTS)24 | 1.18 (0.84 to 1.67) | 1.20 (0.81 to 1.78) | 1.55 (0.95 to 2.54) |
| Folsom et al (ARIC)26 | 1.18 (0.85 to 1.69) | 1.12 (0.76 to 1.67) | 1.16 (0.71 to 1.90) |
| Stevens et al (UKPDS)8 | 1.19 (0.85 to 1.69) | 1.33 (0.90 to 1.98) | 1.39 (0.85 to 2.27) |
Displayed are the observed 5-year risks and the expected to observed ratio for each recalibrated risk score.
ADVANCE, Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation; ARIC, Atherosclerosis Risk in Communities; CHD, coronary heart disease; CHS, Cardiovascular Health Study; CVD, cardiovascular disease; DARTS, Diabetes Audit and Research in Tayside Scotland; DCS, Diabetes Cohort Study; HKDR, Hong Kong Diabetes Register; NDR, National Diabetes Registry; SMART, Secondary Manifestations of ARTerial disease; UKPDS, UK Prospective Diabetes Study.